Anti-CD73 and Anti-HER2 Antibody Combination for Gastric Cancer
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for gastric cancer, particularly those that overexpress the HER2 oncogene, do not provide maximal efficacy, and existing anti-CD73 antibodies face challenges due to non-specificity and toxicity issues, as well as the difficulty in distinguishing between Fc-mediated effects and potential blocking effects.
Innovation Solution
Administering a combination of an antibody that neutralizes the 5′-ectonucleotidase activity of human CD73 protein and an antibody that binds human HER2 protein, optionally with a chemotherapy agent, to inhibit tumor growth and sensitize cancer cells to treatment, while managing the timing and dosing to maximize therapeutic effect.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If anti-CD73 antibodies are used to treat gastric cancer, then tumor growth inhibition is achieved, but non-specificity and toxicity issues arise
Solution Approach 1:
The patent combines anti-CD73 antibodies with anti-HER2 antibodies in a dual-targeted therapy regimen. This merging of two specific targeting approaches allows selective inhibition of tumor growth through both CD73 and HER2 pathways while reducing off-target effects and toxicity associated with single high-dose therapies.
Solution Approach 2:
The patent employs antibodies with specific binding characteristics tailored to target CD73 and HER2 proteins selectively expressed on gastric cancer cells. By using locally optimized antibody properties (specificity, affinity, isotype), the treatment achieves high tumor selectivity while minimizing systemic toxicity.
2Reliability
If anti-CD73 antibodies are used to treat gastric cancer, then therapeutic effect is improved, but difficulty in distinguishing Fc-mediated effects from blocking effects occurs
Solution Approach 1:
The patent segments the therapeutic mechanism into distinct components by using different antibody isotypes with known Fc-mediated activity profiles. This allows researchers to attribute specific effects to either CD73 blocking or Fc-mediated mechanisms based on the antibody class used, simplifying mechanism differentiation.
Solution Approach 2:
The patent uses the antibody Fc region as a controlled intermediary variable. By selecting specific isotypes (e.g., IgG1 with high Fc activity vs. IgG4 with low Fc activity), the study design allows clear differentiation between Fc-mediated effects and direct CD73 blocking effects, as the Fc region acts as a known mediator with predictable behavior.
3Reliability
If combination therapy with anti-CD73 and anti-HER2 antibodies is administered, then treatment efficacy is maximized, but treatment complexity increases
Solution Approach 1:
The patent employs a multi-functional treatment approach where the combination of anti-CD73 and anti-HER2 antibodies targets multiple pathways simultaneously (adenosine production inhibition and HER2 signaling blockade). This universal targeting strategy maximizes efficacy across diverse gastric cancer subtypes while using standardized antibody administration protocols.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach effectively reduces gastric cancer growth, enhances immune response, and improves treatment outcomes by targeting CD73 and HER2 simultaneously, potentially offering a more effective regimen than existing therapies.
Implementation Method 1
CD73 catalyzes the conversion of AMP to adenosine
Implementation Method 2
an antibody that binds human HER2 protein
Data Source
AI summary
The disclosure relates to methods and compositions for the treatment of cancer. Specifically, the disclosure relates to methods for administering anti-CD73 antibodies, and to methods for using anti-CD73 antibodies for the treatment of cancers, preferably HER2-positive gastric adenocarcinoma or a gastroesophageal junction adenocarcinoma in an individual.